MARKET

MDWD

MDWD

Mediwound
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.460
-0.070
-1.98%
Closed 16:00 09/23 EDT
OPEN
3.500
PREV CLOSE
3.530
HIGH
3.575
LOW
3.460
VOLUME
155.73K
TURNOVER
--
52 WEEK HIGH
6.22
52 WEEK LOW
3.100
MARKET CAP
94.27M
P/E (TTM)
-9.6433
1D
5D
1M
3M
1Y
5Y
MediWound to Present at Upcoming Investor Conferences
MediWound Ltd. (Nasdaq: MDWD) (the "Company"), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following investor confe...
GlobeNewswire · 09/03 20:14
Aegis Capital Maintains Buy on MediWound, Lowers Price Target to $9
Aegis Capital maintains MediWound (NASDAQ:MDWD) with a Buy and lowers the price target from $10 to $9.
Benzinga · 08/17 15:59
MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Have Been Cutting Their Estimates
Last week, you might have seen that MediWound Ltd. ( NASDAQ:MDWD ) released its second-quarter result to the market...
Simply Wall St. · 08/12 05:44
HC Wainwright & Co. Maintains Buy on MediWound, Lowers Price Target to $6.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:MDWD) with a Buy and lowers the price target from $7 to $6.5.
Benzinga · 08/11 10:35
MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/10 12:25
BRIEF-Mediwound Reports Second Quarter Financial Results
reuters.com · 08/10 11:18
-- Earnings Flash (MDWD) MEDIWOUND Posts Q2 Revenue $6.1M, vs. Street Est of $5.63M
MT Newswires · 08/10 07:11
MediWound's Earnings: A Preview
On Tuesday, August 10, MediWound (NASDAQ:MDWD) will release its latest earnings report. Benzinga's outlook for MediWound is included in the following report.
Benzinga · 08/09 15:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDWD. Analyze the recent business situations of Mediwound through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDWD stock price target is 6.92 with a high estimate of 9.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 38
Institutional Holdings: 4.17M
% Owned: 15.32%
Shares Outstanding: 27.25M
TypeInstitutionsShares
Increased
7
124.53K
New
7
565.33K
Decreased
8
626.38K
Sold Out
9
1.13M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.98%
Pharmaceuticals & Medical Research
+1.22%
Key Executives
Chairman/Independent Director
Stephen Wills
Chief Executive Officer
Sharon Malka
Chief Financial Officer
Boaz Gur-Lavie
Executive Vice President/General Counsel/Secretary
Yaron Meyer
Chief Technology Officer
Lior Rosenberg
Other
Ety Klinger
Director
David Fox
Director
Ofer Gonen
Director
Samuel Moed
Director
Assaf Segal
Independent Director
Vickie Driver
Independent Director
Sharon Kochan
Independent Director
Nissim Mashiach
No Data
About MDWD
MediWound Ltd. is a Israel-based biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Webull offers kinds of Mediwound Ltd stock information, including NASDAQ:MDWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDWD stock methods without spending real money on the virtual paper trading platform.